The natural history of Crohn's disease: Who holds the crystal ball?

Gut

Volumn 61, Issue 8, 2012, Pages 1106-1107

  Van Assche, Gert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

BIOLOGICAL THERAPY; COHORT ANALYSIS; CROHN DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; STOMA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 84863718825     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302187     Document Type: Note

References (13)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
2. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6. (Pubitemid 43374514)
3. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43:948-54.
4. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A):5-36.
5. Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn's disease over 15 years. Gut 2012;61:1140-5
6. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype diagnosis predicts recurrence rates Crohn's disease. Gut 2006;55:1124-30. (Pubitemid 44085679)
7. Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8. (Pubitemid 350181602)
8. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
9. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008;371:660-7. (Pubitemid 351284485)
10. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
11. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
12. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
13. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8.